PharmaLex (Cencora) shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what PharmaLex (Cencora) publishes on its own site (www.pharmalex.com/pharmalex-industry-sectors/medtech · www.pharmalex.com/pharmalex-solutions/local-affiliate-services · www.pharmalex.com/country/brazil), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.
What PharmaLex (Cencora) publishes
PharmaLex, part of Cencora, is a global regulatory consultancy. Its MedTech page says it arranges authorized representative and license holder services in "multiple markets," and its local-affiliate page names emerging Latin American markets "such as Brazil and Mexico." PharmaLex has a Brazil country page. The public pages do not list INVIMA, ANMAT, ISP or DIGEMID holder services one by one, and much of the MedTech content is EU MDR/IVDR work.
PharmaLex (Cencora) vs bioaccess®
| Dimension | PharmaLex (Cencora) | bioaccess® |
|---|---|---|
| Public product | Global MedTech regulatory consulting, authorized representative / license holder arranged in multiple markets | LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately) |
| Geography | Brazil and Mexico named; others not enumerated | 19 LATAM markets |
| Public pricing | Enterprise / statement of work | USD 7,500 per year per country for the first device family |
| Holder vs distributor | See the provider’s own terms | Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage |
| Bridge from a clinical trial | None published | Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients |
Where each one fits
If you are a large manufacturer already buying EU MDR and pharmacovigilance work from PharmaLex, adding Brazil or Mexico through the same account is fine.
The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.
One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.
Competitor facts from the PharmaLex (Cencora) public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.
Leave a Reply